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Open Forum Infectious Diseases
MAJOR ARTICLE

Yasir Hamad , Lee Connor, Thomas C. Bailey, and Ige A. George
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA

Background.
Staphylococcus aureus bloodstream infections (BSIs) are associated with significant morbidity and mortality.
Ceftriaxone is convenient for outpatient parenteral antimicrobial therapy (OPAT), but data for this indication are limited.
Methods.
Adult patients with methicillin-susceptible Staphylococcus aureus (MSSA) BSI discharged on OPAT with cefazolin,
oxacillin, or ceftriaxone for at least 7 days were included. We compared outcomes of ceftriaxone vs either oxacillin or cefazolin.
Ninety-day all-cause mortality, readmission due to MSSA infection, and microbiological failure were examined as a composite outcome and compared among groups. Rates of antibiotic switches due to intolerance were assessed.
Results.
Of 243 patients included, 148 (61%) were discharged on ceftriaxone and 95 (39%) were discharged on either oxacillin
or cefazolin. The ceftriaxone group had lower rates of intensive care unit care, endocarditis, and shorter duration of bacteremia, but
higher rates of cancer diagnoses. There was no significant difference in the composite adverse outcome in the oxacillin or cefazolin
group vs the ceftriaxone group (18 [19%] vs 31 [21%]; P = .70), comprising microbiological failure (6 [6.3%] vs 9 [6.1%]; P = .94),
90-day all-cause mortality (7 [7.4%] vs 15 [10.1%]; P = .46), and readmission due to MSSA infection (10 [10.5%] vs 13 [8.8%];
P = .65). Antibiotic intolerance necessitating a change was similar between the 2 groups (4 [4.2%] vs 6 [4.1%]; P = .95).
Conclusions.
For patients with MSSA BSI discharged on OPAT, within the limitations of the small numbers and retrospective design we did not find a significant difference in outcomes for ceftriaxone therapy when compared with oxacillin or cefazolin therapy.
Keywords.
cefazolin; ceftriaxone; MSSA bacteremia; OPAT; oxacillin.
Staphylococcus aureus is a leading cause of both communityonset and hospital-acquired bloodstream infections (BSIs) [1].
S. aureus BSI is often associated with complications such as
dissemination to distant sites and endocarditis, consequently
leading to morbidity and mortality [2]. Due to the risk of recurrence, prolonged parenteral therapy with a beta-lactamaseresistant penicillin (nafcillin or oxacillin) or cefazolin is the
guideline-suggested care to treat methicillin-susceptible S. aureus (MSSA) BSI [3]. Ceftriaxone has been shown to be an
effective treatment for serious MSSA infections in previous
studies and has a Food and Drug Administration–labeled indication for MSSA septicemia [4, 5]. A retrospective study of 124
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patients with MSSA bone and joint infections at our institution
comparing ceftriaxone vs oxacillin found that ceftriaxone had
similar rates of success and was better tolerated than oxacillin
[6]. Few studies have compared ceftriaxone with either nafcillin
or cefazolin in MSSA BSIs. In a study by Patel et al., clinical
and microbiological cure rates were similar among 51 patients
treated with nafcillin or cefazolin and 42 patients treated with
ceftriaxone [7]. Carr et al. reported more adverse outcomes in
33 patients with MSSA BSI treated with ceftriaxone compared
with 38 treated with cefazolin, but the 2 groups were different,
with many of the patients in the ceftriaxone group being sent to
skilled nursing facilities that had higher readmission rates [8].
The optimal choice of beta-lactam therapy for MSSA bloodstream infection is unclear. When compared with nafcillin, oxacillin, or cefazolin, ceftriaxone has benefits in terms of lower
costs, once- or twice-daily administration, and a favorable
long-term side effect profile, making it an attractive drug for
outpatient parenteral antibiotic therapy (OPAT) [4, 6]. Whether
once- or twice-daily ceftriaxone therapy results in acceptable
outcomes for patients with MSSA BSI is an open question [9,
10]. This study compared outcomes of MSSA BSI among patients discharged on ceftriaxone compared with oxacillin or
cefazolin.
Ceftriaxone Use in MSSA Bacteremia • ofid • 1
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Outcomes of Outpatient Parenteral Antimicrobial
Therapy With Ceftriaxone for Methicillin-Susceptible
Staphylococcus aureus Bloodstream Infections—A SingleCenter Observational Study

METHODS
Study Design and Patient Population

Clinical Data Collection

Clinical data were collected through review of inpatient and
outpatient electronic medical records using Research Electronic
Data Capture (REDCap) electronic data capture tools hosted at
Washington University in St Louis. REDCap is a secure, Webbased software platform designed to support data capture for
research studies [11]. Clinical data abstracted by 3 authors
(L.C., Y.H., I.A.G.) included demographic characteristics, patient comorbidities, clinical presentation, diagnostic evaluations (including laboratory results, microbiology results, and
imaging studies), antibiotics used, and planned duration of
treatment. In addition, outpatient clinical parameters assessed
in infectious diseases (at 2–3 weeks after discharge and/or at the
end of therapy) and surgical subspecialty clinics included signs
and symptoms of infection noted during the follow-up visit(s),
documentation of adverse events related to antibiotic administration, laboratory data, imaging studies, change or extension
of intravenous (IV) antibiotics, and oral suppressive antibiotic
recommendations. These data were used to determine whether
there was evidence of successful treatment or treatment failure.
Outcomes were compared between the 2 groups—those who
received oxacillin or cefazolin vs those who received ceftriaxone
on discharge.
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Ninety-day all-cause mortality was defined as death occurring
within 90 days of discharge determined by electronic medical
record review. Clinical failure was defined as unanticipated
readmission or surgical intervention related to MSSA infection within 90 days of discharge from the index admission.
Microbiological failure was defined as subsequent isolation
of MSSA from any sterile site within 90 days of completion of
treatment. The composite outcome for treatment failure was
defined by death or clinical or microbiological failure within
the specified periods above.
Comorbid conditions were evaluated using the Elixhauser
Comorbidity Index, which is based on the International
Classification of Diseases, 9th and 10th Revisions, Clinical
Modification (ICD-9-CM and ICD-10-CM), codes. ICD codes
were supplemented by chart review to identify concurrent infections including skin and soft tissue infections, endocarditis,
and osteomyelitis, as well as ESRD, central line–associated
bloodstream infections (CLABSIs), intravenous drug use, and
the presence of prosthetic materials. The primary source of infection was identified from concurrent positive microbiologic
specimens for MSSA or based upon consistent clinical signs and
symptoms and radiographic evidence. Endocarditis was defined
by evidence of a vegetation on cardiac valves identified by echocardiography, along with concomitant MSSA bacteremia, or
if the ID physician suspected infective endocarditis and a decision was made to treat as infective endocarditis. The Elixhauser
Comorbidity Index (ECI), incorporating comorbidities to predict inpatient mortality, was used as a composite variable to
associate risk factors for the composite outcome [12]. Source
control was felt to be achieved if the reviewing physician ascertained that the focus of infection had been removed (eg, abscess
drained, central venous catheter removed).
Statistical Analysis

Descriptive statistics were used for the demographic and clinical
characteristics of the study population. Categorical data were
compared using the chi-square test or Fisher exact test, and
continuous variables were compared using the Student t test or
Mann-Whitney U test, as appropriate. Patients with proven or
suspected endocarditis were evaluated as a subgroup, as these
were potentially sicker patients. Potential risk factors for treatment failure were analyzed for the 2 groups using univariable
and multivariable Cox proportional hazards models. The proportional hazards assumption was evaluated for the outcome
variables using visual inspection of log-log survival curves
[13]. For the multivariable model, variables were specified by
selecting clinically meaningful factors that could potentially be
associated with treatment failure, which included comorbidity
indices, choice of antibiotics, discharge destination, source control, and evidence of endocarditis. Patients were censored at
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We performed a retrospective cohort study of adults with
MSSA BSI who were discharged from Barnes-Jewish Hospital
on OPAT and followed by the Washington University
Infectious Disease service over a 4.5-year period from
December 1, 2014, to April 30, 2019. Barnes-Jewish Hospital
is a 1350-bed tertiary care medical center located in St. Louis,
Missouri. Patients were identified from the OPAT registry,
which includes all patients who are seen by Infectious Disease
physicians and discharged on parenteral antibiotics. Patients
were included if they had ≥1 positive blood culture for MSSA
and were discharged on 1 of the 3 antibiotics of interest:
ceftriaxone 2–4 g daily, oxacillin 2 g every 4 hours, or cefazolin
2 g every 8 hours or equivalent, adjusted for renal injury (of
note, nafcillin is not on the hospital formulary). If the patient
had multiple admissions for MSSA BSI, the first admission
was included as the index admission. Patients were excluded
if they had polymicrobial bloodstream infections, had <7 days
of OPAT, or had end-stage renal disease (ESRD) on hemodialysis (HD). HD patients were excluded as they could have been
preferentially treated with either cefazolin due to the ease of
dosing or ceftriaxone, given that its main route of excretion
is not renal. Patients were identified from the Washington
University Infectious Diseases OPAT database. All patients
were seen by Infectious Disease providers during the index
hospitalization.

Variable Definitions

the time of last follow-up or 90 days post-treatment, whichever
came first.
Statistical significance was set at P < .05. All analyses were
performed using SAS 9.4 software (Cary, NC, USA).
Patient Consent Statement

RESULTS

During the study period, 243 patients with MSSA BSI received
1 of the 3 antibiotics of interest for at least 7 days as part of
Table 1.

Clinical Characteristics and Outcomes of 243 Patients in the Ceftriaxone and Oxacillin-Cefazolin Treatment Groups

Variable, No. (%) or Median (IQR)
Age, y
Sex (male)
Race (White)
Body mass index, kg/m2

Total (n = 243)
59.6 (47.8–70)
154 (63.4)
187 (77.4)
29.1 (23.5–35.6)

Oxacillin-Cefazolin (n = 95 [39%])
57.1 (46.4–68.2)
61 (64.2)
73 (76.8)
29.1 (24.2–32.9)

Ceftriaxone (n = 148 [61%])
61.3 (48.9–71.5)

P Value
.08

93 (62.8)

.83

115 (77.7)

.88

27.3 (23.5–33.3)

.84

AIDS

5 (2.1)

1 (1.1)

4 (2.7)

.27

CHF

49 (20.6)

20 (21.7)

29 (19.9)

.73

Diabetes

59 (24.3)

20 (21.1)

39 (26.4)

.35

Acute renal failure in the past year

43 (18.1)

16 (17.4)

27 (18.5)

.83

Solid tumors

51 (21)

8 (8.4)

43 (29.1)

<.01

Hematological malignancies

14 (5.9)

6 (6.5)

8 (5.5)

Valvular heart disease

50 (21)

31 (33.7)

Length of stay after positive blood culture

9.9 (6.6–16.2)

Intensive care unit stay

89 (36.6)

46 (48.4)

Recent hospitalization in the last 30 d

43 (17.7)

Ventilator support
Presence of CIED

.74

19 (13)

<.01

7.4 (5.5–12.2)

<.01

43 (29.1)

<.01

18 (19)

25 (16.9)

.68

40 (16.5)

20 (21.1)

20 (13.5)

.12

23 (9.5)

12 (12.6)

11 (7.4)

.18

15.3 (9.9–20.8)

CIED explanted

7 (30.4)

4 (33.3)

3 (27.3)

.99

LVAD

6 (2.5)

2 (2.1)

4 (2.7)

.32

228 (93.8)

86 (90.5)

142 (95.6)

Transthoracic echocardiography
Transesophageal echocardiography

93 (38.3)

Source control not achieved

23 (9.5)

Total IV antibiotic course duration

42 (34–44)

42 (42–44)

42 (28–43)

6 (4–11)

9 (5–15)

5 (4–9)

Inpatient IV antibiotic duration

56 (59)
9 (9.5)

.09

37 (25)

<.01

14 (9.5)

.99
.01
<.01

OPAT duration

34 (24–39)

34 (27- 39)

34 (24–39)

.70

Discharge to post–acute care facility

83 (34.2)

32 (33.7)

51 (34.5)

.90

Bacteremia duration, d

1.5 (1–2.4)

1.7 (1–2.9)

1.3 (1–2.2)

.04

CVC present

72 (29.6)

21 (22.1)

51 (34.5)

.04

Percentage of CVC removed

67 (93.1)

21 (100)

46 (90.2)

.31

Source/site of infection
Primary bacteremia

40 (16.5)

13 (13.7)

27 (18.2)

.35

Central line–associated bacteremia

70 (28.8)

22 (23.2)

48 (32.4)

.12

Infection of prosthetic material

26 (10.7)

11 (11.6)

15 (10.1)

.72

Skin & soft tissue infection

33 (13.6)

9 (9.5)

24 (16.2)

.13

Surgical site infections

16 (6.6)

3 (3.2)

13 (8.8)

.05

Osteomyelitis

40 (16.5)

20 (21.1)

20 (13.5)

.12

Septic arthritis/prosthetic joint infection

28 (11.5)

12 (12.6)

16 (10.8)

.66

Epidural abscess

13 (5.4)

6 (6.3)

7 (4.7)

.59

Endocarditis

83 (34.2)

41 (43.2)

42 (28.4)

.02

Ceftriaxone Use in MSSA Bacteremia • ofid • 3

Downloaded from https://academic.oup.com/ofid/article/7/9/ofaa341/5892290 by Washington University at St Louis user on 09 October 2020

The Washington University School of Medicine Human
Research Protection Office (HRPO) approved this study.
Informed consent was not required for this study according to
the HRPO regulations given its minimal risk and retrospective
study design.

OPAT. Of these, 148 (61%) received ceftriaxone while 95 (39%)
patients received either oxacillin (56) or cefazolin (39). The
mean age was 59.6 years, and patients were predominantly male
(63%) and White (77%). The most common comorbidities
were diabetes mellitus (59 [24%]), solid tumor (51 [21%]), valvular heart disease (50 [21%]), and congestive heart failure (49
[20%]). Over a third of patients (89 [37%]) required intensive
care unit care during the index hospitalization, including 40
(16%) who required mechanical ventilation (Table 1). There
were 15 (6.2%) patients who were lost to follow-up during the
course of the study, 8 (5.4%) in the ceftriaxone group and 7
(7.4%) in the oxacillin-cefazolin group.
Endocarditis complicated many of the BSIs, occurring in 83
(34%) patients. MSSA bacteremias were associated with central
venous catheters (CVCs) in 70 (29%) patients and bone and

Table 1. Continued
Variable, No. (%) or Median (IQR)
Valve replaced

Total (n = 243)

Oxacillin-Cefazolin (n = 95 [39%])

17 (7)

15 (15.8)

Ceftriaxone (n = 148 [61%])

P Value

2 (1.4)

<.01

Inpatient antibiotics received >48 h
80 (32)

80 (53)

<.01

Oxacillin

53 (21)

40 (41)

13 (9)

<.01

Cefazolin

33 (13)

23 (24)

10 (7)

<.01

Cefepime

3 (1)

0

3 (2)

.28

12 (5)

3 (3)

9 (6)

.38

8 (3)

2 (2)

6 (4)

.49

25 (10)

7 (7)

18 (12)

.24

4 (2)

3 (3)

1 (1)

.30

Meropenem
Piperacillin-tazobactam
Vancomycin
Linezolid

0

Inpatient laboratory values at discharge
CRP

145 (68–223)

131 (54–199)

156 (71–234)

ESR

71 (45–95)

71 (38–94)

71 (53–97)

White blood count

7.9 (5.7–10.6)

7.9 (5.6–10)

Platelets

.32
.24

8 (5.7–10.9)

.75
.11

262 (157–367)

295 (159–393)

245 (154–332)

Creatinine clearance

97 (66–132)

88 (54–128)

102 (73–134)

Oral antibiotic suppression after OPAT

44 (18.1)

25 (26)

19 (13)

.10
<.01

Outcomes
Change in antibiotics due to toxicity

11 (4.5)

4 (4.2)

6 (4.1)

.95

Microbiological failure

15 (6.2)

6 (6.3)

9 (6.1)

.94

90-d all-cause mortality

22 (9.1)

7 (7.4)

15 (10.1)

.46

Readmitted due to MSSA infection

23 (9.5)

10 (10.5)

13 (8.8)

.65

Composite

49 (20.2)

18 (19)

31 (21)

.70

Abbreviations: CHF, congestive heart failure; CIED, cardiovascular implantable electronic device; CRP, C-reactive protein; CVC, central venous catheter; ESR, erythrocyte sedimentation
rate; IQR, interquartile range; IV, intravenous; LVAD, Left ventricular assist device; MSSA, methicillin-susceptible Staphylococcus aureus; OPAT, outpatient parenteral antimicrobial therapy.

joint infections in 40 (16%) patients and were determined to
be primary bacteremia in 40 (16%) patients. Ninety-three percent (67) of CVCs were removed in patients with concurrent
bacteremia, and 7 (30%) cardiac implantable electronic devices
(CIEDs) were removed. Patients were treated for a median (interquartile range [IQR]) of 42 (34–44) days from the time of
culture clearance or source control achievement (Table 1). One
hundred thirty-nine patients (93.2%) on ceftriaxone received
2 g daily, while 10 patients (6.8%) received 2 g every 12 hours.
Comparison of the Treatment Groups

Patients in the ceftriaxone and oxacillin-cefazolin groups had
similar overall baseline and clinical characteristics. However,
the ceftriaxone group had lower rates of intensive care unit care
(29.1% vs 48.4%; P < .01), shorter duration of bacteremia (1.3
vs 1.7 days; P = .04), and shorter intravenous antibiotic duration
(median [IQR], 42 [28–43] vs 42 [42–44] days; P = .01). The
ceftriaxone group also had lower rates of valvular heart diseases
(13% vs 33.7%; P < .01), TEEs performed (25% vs 59%; P < .01),
endocarditis (28.4% vs 43.2%; P = .02), and subsequent valve
replacement surgeries (1.4% vs 15.8%; P < .01), but had more
solid tumors (29.1% vs 8.4%; P < .01) (Table 1). Both groups had
similar rates of discharge to post–acute care facilities (34.5% vs
33.7%; P = .90). Of patients discharged on IV ceftriaxone, 23
(16%) received oxacillin or cefazolin for more than 48 hours
while inpatient. Patients in the oxacillin-cefazolin group were
more likely to have received oral antibiotics for suppression
4 • ofid • Hamad et al

after the end of OPAT (25 [26%] vs 19 [13%]; P ≤ .01) (Table 1).
The most common antibiotics used for suppression were doxycycline 26 (60%), cephalexin 11 (26%), and trimethoprim/sulfamethoxazole 3 (7%).

Outcomes

The primary composite outcome (death, readmission related
to MSSA infection, or microbiological failure within 90 days
of hospital discharge) occurred in 49 (20%) of patients.
Microbiological failure occurred in 15 (6%), 90-day all-cause
mortality occurred in 22 (9%), and hospital readmission due
to MSSA infection occurred in 23 (10%) patients. Changes in
antibiotics due to toxicity occurred in 11 (4.5%) patients, 6
(4.1%) in the ceftriaxone group and 4 (4.2%) in the oxacillincefazolin group (P = .95). Toxicities in the ceftriaxone group
were skin rashes in 3 patients (1 with concomitant eosinophilia), acute kidney injury in 2, and nausea in 1, while in the
oxacillin-cefazolin group, the reasons for switch were neutropenia in 2 patients and acute kidney injury and hepatotoxicity
in 1 each. There were no significant differences in microbiological failure (6 [6.3%] vs 9 [6.1%]; P = .94), 90-day all-cause
mortality (7 [7.4%] vs 15 [10.1%]; P = .46), readmission due
to an MSSA infection (10 [10.5%] vs 13 [8.8%]; P = .65), or
composite outcome (18 [19%] vs 31 [21%]; P = .70) among the
oxacillin-cefazolin and ceftriaxone treatment groups, respectively (Table 1).

Downloaded from https://academic.oup.com/ofid/article/7/9/ofaa341/5892290 by Washington University at St Louis user on 09 October 2020

Ceftriaxone

Table 2. Multivariable Risk Factors Associated With Treatment Failure
(Composite of Death and Clinical/Microbiological Failure)
Multivariate Analysis
Hazard Ratio

95% CI

Age >65 y

0.907

0.484–1.700

.76

Elixhauser Comorbidity Index

1.015

0.993–1.039

.19

Variable

P Value

0.884

0.471–1.660

.70

1.080

0.426–2.737

.87

Discharged on ceftriaxone

0.994

0.537–1.841

.99

Discharge to post–acute care facility

1.769

0.974–3.214

.06

In the Cox regression model, the use of ceftriaxone was not
associated with composite outcome of treatment failure in either univariate (hazard ratio [HR], 1.062; 95% CI, 0.594–1.898)
or multivariate analysis (HR, 0.994; 95% CI, 0.537–1.841)
(Table 2).
Endocarditis Subgroup

Most patients (228 [94%]) underwent transthoracic echocardiography (TTE), while 93 (38%) underwent transesophageal
echocardiography (TEE) to evaluate for endocarditis.
Endocarditis was suspected in 83 (34%) patients with concomitant MSSA BSI. Echocardiography confirmed the suspicion in 54 (65%) patients, while 29 (35%) did not have a TEE
done and were treated for endocarditis. Forty-two (50.6%) were
treated with ceftriaxone, while 41 (49.4%) were treated with oxacillin/cefazolin. When analyzing the endocarditis group, the
ceftriaxone group had higher rates of 90-day all-cause mortality
(6 [14.3%] vs 1 [2.4%]; P = .11) and composite outcome (11
[25.6%] vs 4 [10%]; P = .17). The risks of microbiological failure
and hospital readmission due to MSSA infection did not differ
between the 2 groups (Table 3).
DISCUSSION

Although widely accepted as standard treatment for MSSA BSI,
the quality of evidence for preferential use of antistaphylococcal
beta-lactam antibiotics like oxacillin, nafcillin, or cefazolin is
poor and relies mostly on observational data [10]. At our institution, ceftriaxone is increasingly being used to treat MSSA
infections. This practice, driven by practical implications of
cost and convenience of outpatient treatment, was evaluated

Table 3.   Outcomes of the Ceftriaxone Group vs Oxacillin-Cefazolin Group in Patients Diagnosed With Endocarditis
Outcome Variables

Total (n = 83), No. (%)

Oxacillin-Cefazolin (n = 41), No. (%)

Ceftriaxone (n = 42), No. (%)

P Value

Microbiological failure

6 (7.2)

3 (7.3)

3 (7.1)

.99

90-d all-cause mortality

7 (8.4)

1 (2.4)

6 (14.3)

.11

Readmitted due to MSSA infection

6 (7.2)

3 (7.3)

3 (7.1)

.99

15 (18.1)

4 (10)

11 (25.6)

.17

1 (2.4)

.99

Composite
Change in antibiotics due to toxicity after discharge

1 (1.2)

0

Abbreviation: MSSA, methicillin-susceptible Staphylococcus aureus.
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Endocarditis
Lack of source control

in a retrospective review done at our institution of 124 MSSA
osteoarticular infections that documented favorable treatment
outcomes with ceftriaxone [6, 14].
This study demonstrates that in selected patients discharged
on OPAT, ceftriaxone is a viable option for MSSA BSI when
compared with oxacillin and cefazolin. We did not detect a
difference in the composite outcome for treatment failure (including mortality, readmissions due to infection, and microbiological failure) between the oxacillin/cefazolin group (19%)
and the ceftriaxone group (21%; P = .70) (Table 1). These results were very similar to the retrospective study of 93 male
patients with MSSA bacteremia by Patel et al., where there
were no significant differences between patients treated with
ceftriaxone (n = 42) compared with those treated with nafcillin
or cefazolin (n = 51) in either microbiological (95.2% vs 94.1%;
P = .81) or clinical cure rates (83.3% vs 74.5%; P = .30). Our results conflict with those of Carr et al., who reported significantly
higher failure rates among patients with MSSA BSI receiving
ceftriaxone (n = 33) compared with cefazolin (n = 38; 54.5%
vs 28.9%; P = .029). However, in this study, there were more
patients on ceftriaxone who were discharged to an external
skilled nursing facility (SNF) as compared with an attached
community living center (CLC), which was shown to be a risk
factor for treatment failure. The authors argue that the difference could be due to closer monitoring and availability of ID
physicians in the attached CLC compared with the SNF. In our
study, the rates of discharge to post–acute care facilities (34.5%
vs 33.7%; P = .90) were similar in both the comparison groups,
but there was a trend for treatment failure in patients discharged
to a post–acute care facility (HR, 1.769) (Table 2). Suboptimal
outcomes (eg, unplanned hospitalizations or line-associated infections) have been described in patients discharged on OPAT
to post–acute care facilities and could indicate a gap in the continuity of care and adequate laboratory monitoring of adverse
events [15, 16].
Although there were no significant differences in the failure
rates between the 2 groups in our study overall, among the
subgroup of patients with endocarditis there was a trend toward more adverse events in the ceftriaxone group (25.6% vs
10%; P = .17). Possible reasons could be that the higher minimal inhibitory concentration distributions of ceftriaxone
tend to be associated with a lower MSSA bactericidal
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group being inherently better than in the comparator group. We
did not see significant differences in outcomes between treatment groups even after adjusting for different factors including
antibiotic choice and endocarditis in the multivariable model.
Another limitation is that this study addresses the question of
antibiotic choice after discharge from the hospital (OPAT) and
does not compare the antibiotic choices made while inpatient.
We felt that this was a more relevant question to answer, as
ceftriaxone offers more convenient dosing and has a cost advantage, which makes it an attractive option for OPAT [6]. In
the study by Wieland et al., the median cost estimate for the antibiotic course was significantly lower in the ceftriaxone group
compared with the oxacillin group ($6720 vs $11 329; P < .001).
We were also not able to make meaningful comparisons regarding the optimal dosing for use of ceftriaxone due to the
sparse number of patients (<7%) receiving doses >2 g/d. There
is a concern that the broader coverage of ceftriaxone compared
with oxacillin and cefazolin would lead to antibiotic resistance
and would be against good stewardship practice. Lastly, there is
a possibility of poor adherence to OPAT therapy, and this was
not measured for the study participants.
Despite these limitations, this is the largest study to date comparing ceftriaxone with other antibiotics of interest in MSSA
bacteremia. Infectious Disease physicians saw all included patients, and hence there is some degree of homogeneity in the
workup, management, and treatment duration of these patients.
In a recent survey of OPAT patients at our institution, receiving
a simpler regimen once or twice daily was significantly associated with better adherence when compared with more frequent
dosing regimens (76% vs 17% of the adherent and nonadherent
groups, respectively; P = .01) [24]. Thus, patients are more likely
to adhere to ceftriaxone as compared with more frequent dosing
regimens of oxacillin or cefazolin. Furthermore, once-daily
regimens facilitate patients receiving therapy at an infusion
center, which is the only outpatient option for Medicare patients
without a significant out-of-pocket cost [22]. The results of this
study would be encouraging especially for Medicare patients
and for those centers that offer self-directed OPAT, where cost
and ease of dosing are important considerations [25, 26].
CONCLUSIONS

Ceftriaxone might be a reasonable alternative for the treatment of patients with MSSA bacteremia discharged on OPAT,
and when compared with oxacillin or cefazolin, no significant
difference in outcomes was noted in this retrospective study.
There was a trend toward adverse outcomes in patients with endocarditis, although it was not statistically significant. Further
studies, possibly prospective comparisons, should be undertaken to further document clinical equivalence, optimal dosing,
and cost effectiveness of ceftriaxone considering the advantages
of ease of dosing and excellent tolerability.
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effect when compared with cefazolin in pharmacodynamics
models, and such an effect might have greater implications
in endocarditis patients [17]. Our microbiology laboratory
tests for cefoxitin susceptibility as a surrogate for cefazolin,
ceftriaxone, and oxacillin susceptibilities, consistent with the
Clinical and Laboratory Standards Institute guidelines [18].
In a study evaluating pharmacokinetic/pharmacodynamic
end points of commonly used antibiotics for S. aureus, 5%
of MSSA isolates tested were ceftriaxone-nonsusceptible and
in a modeling-based prediction tool; for ceftriaxone, only a
higher dose of 2000 mg q12h produced a cumulative fraction
of response (CFR) ≥90% [19]. Another pharmacologic argument is that ceftriaxone is highly protein bound (up to 95%)
and hence has decreased free drug available to exhibit antibacterial activity, especially when maintaining a high serum
level is needed to penetrate deeper tissues such as vegetations
in endocarditis. However, cefazolin is around 80% protein
bound, and oxacillin is around 94% protein bound, so this
theory should affect all the 3 antibiotics of interest equally
[20]. Although not statistically significant, given the trend
for worse outcomes in patients with endocarditis and the
plausible pharmacodynamic arguments to explain this,
twice-daily ceftriaxone therapy should be further studied in
this setting. The overall 90-day mortality (9%) in our cohort
was lower when compared with studies in the United States
that have reported 90-day mortality (25%–26%) in S. aureus
bacteremias [17, 21]. This is likely due to the fact that we included patients who survived the inpatient stay and were well
enough to be discharged on OPAT.
There are several limitations to this study. This is a retrospective single-center study, and we are unable to prove
noninferiority of ceftriaxone. We would need 332 patients in
each treatment arm, with estimated 85% survival, accepting a
10% difference in outcomes, to have 95% power (with α = .025)
to prove noninferiority [22]. There could be a difference in the
treatment outcomes that we are unable to detect due to the relatively small numbers in our study. However, we feel that this
reflects a pragmatic comparison of 2 concurrent treatment
practices in our institution. We observed significant differences
in the baseline characteristics between the 2 treatment groups,
likely due to a selection bias of certain infectious disease physicians’ preference of using oxacillin/cefazolin for complicated
bacteremia. The oxacillin/cefazolin group had a higher proportion of patients with endocarditis (43.2% vs 28.4%; P = .02),
longer length of stay (median days, 15.3 vs 7.4), and longer
duration of bacteremia (median days, 1.7 vs 1.3). Oxacillin/
nafcillin and cefazolin are recommended by treatment guidelines endorsed by the Infectious Diseases Society of America for
treating MSSA endocarditis, and it is likely that physicians when
treating endocarditis follow guideline-recommended antibiotic
selection [23]. The ceftriaxone group had fewer cases of endocarditis, and this may have led to outcomes in the ceftriaxone
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